NASDAQ:WBA

Walgreen Boots Alliance (WBA)

12.05
+0.07 (0.58%)
as of Aug 27, 2025, 11:48:28 pm Market Open.
122 watching
0
COMMENT

They report next week. He hopes they lower expectations. WBA is a great conundrum with great stores and pharmacies on one hand, but Amazon knocks the stuffing out of them.

PAST TOP PICK
(A Top Pick Oct 15/19, Down 31%) Being a value manager in this market is tough. This fits his definition of a value stock. His model price is $56.73 which is a 60% upside. He still owns it. It looks like it is trying to bottom. We need to get past the doubts about the economy.
DON'T BUY

The prescription drugs business is under attack, and the front of store is under attack from Amazon. Doesn't see any catalysts to raise this stock.

DON'T BUY

He has owned CVS instead in the past. This and WBA have been hit hard in recent years from a lingering concern over pressure on drug prices in the U.S. So, both have expanded into drug distribution, not just drug retail. The multiple that the market will pay for either has compressed. So, he prefers other stocks in this space, like Loblaws (which owns Shoppers Drug Mart) Drug. Traditionally, drug retailing is a stable business, but in the U.S. the pricing issue remains an overhang.

COMMENT

He has chosen to exit their holding about a year ago, based on their UK alliance (due to Brexit). He participates in the space with CVS instead, who bought a pharmacy benefits company. CVS has more than 10,000 locations in the US. The company has become vertically integrated, which gives them a long runway. Their "Health Hub" offers medical practitioners to people who would not otherwise have access to one.

DON'T BUY

CVS vs. Walgreens Prefers CVS. Walgreens missed their recent numbers. Walgreens is purely a pharmacy company, which faces competitive threats from Amazon and Walmart. In contrast, CVS is vertically integrated; they bought insurer Aetna for example. Pays a 3% yield. However, CVS did borrow heavily to buy Aetna, but generally CVS is in much better financial shape than Walgreens.

BUY

A disappointing stock over the last few years, especially as Amazon is getting into the space. Recent earnings were in line. They have increased dividends 44 years in a row and trades cheaply at 9 times earnings. He holds it in the portfolio and thinks it is a comfortable buy here, but don't expect a big run up.

COMMENT

CVS vs WBA? He thinks CVS has more growth potential. Both have been relatively poor performers over the past couple of years. The main reason being there are too many pharmacies in the US. With Walmart, Costco and Target getting involved the competition is intense and putting pressure on margins. CVS is worthy of a look following the investment in AETNA, which is helping them diversify. Amazon is expected to enter the space soon.

BUY ON WEAKNESS
He likes the positioning. It's been hurt recently because of the worry over healthcare and costs. However, it is still a good play for the integration.
BUY

WBA-Q vs. CVS-N. He just bought CVS-N. Walgreens is still the pure Walgreen - Boots alliance, pharmacy business, incredibly well run. CVS-N merged with Aetna on the benefits side. The risk on healthcare is always legislation. The US is aging like all western countries. They cover all the bases. Both companies are so well entrenched that it is hard to displace them.

PAST TOP PICK
(A Top Pick Nov 02/18, Down 29%) It's so cheap now. It's a top pick today too.
TOP PICK
$81.26 is his model price, 51% potential upside. Pays a 3.36% dividend. Good earnings. Trades at a low valuation. Good fundamentals. (Analysts’ price target is $58.39)
HOLD
Walgreen move in the UK with Boots was a good move. Pharmaceuticals are important and selling other stuff is great. It will keep growing, especially with the regulation around drug dispensaries. (Analysts’ price target is $58.35)
DON'T BUY

Attractive valuation. Owns CVS Health instead, which is vertically integrated. So CVS is better positioned in the new world of health in the US to bring down costs. CVS trading at 9-10x earnings.

HOLD
Bad news is already factored in. Bringing health care into the mix will give them more sustainable earnings, downturn resistant earnings, and maintain the multiple. Don't rush to sell this.
Showing 46 to 60 of 261 entries